



Nanotechnology for Antimicrobials in Medicine and Agriculture

Guest Editors:

Dr. Gonzalo Tortella

1. Scientific and Technological
Bioresource Nucleus,
Universidad de La Frontera,
Temuco 4811230, Chile
2. Centro de Excelencia en Inv.
Biotecnológica Aplicada al
Medioambiente (CIBAMA),
Universidad de La Frontera,
Temuco 4811230, Chile

Prof. Dr. Amedea B. Seabra

Center for Natural and Human
Sciences (CCNH), Federal
University of ABC (UFABC), Av.
dos Estados, 5001-Bangú, Santo
André 09210-580, SP, Brazil

Deadline for manuscript
submissions:

closed (31 December 2022)

Message from the Guest Editors

Dear Colleagues,

Currently, viral, fungal, or bacterial infections are a major concern for human health, and also for agriculture and food production. Pathogenic microorganisms can cause chronic infections and mortality as has been recently observed with COVID-19. On the other hand, for the food production, the presence of infections translates into crop damages and enormous economic losses.

Driven by the depletion of effective treatments and antibiotic or pesticide resistance due to their excessive use, research on new antimicrobials has seen explosive growth. In this regard, nanomaterials have attracted special attention because of their broad spectrum—e.g., antibacterial, antifungal, or antiviral—which has resulted in significant developments in the science of the control of pathogenic microorganisms.

The key motivation behind this Special Issue on “Nanotechnology for Antimicrobials” is to collect knowledge regarding the research and development of nanomaterials that open new possibilities for effective treatment of diseases from a medical or agricultural point of view.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1
(*General Pharmacology, Toxicology and Pharmaceutics*)

Contact Us

Antibiotics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)